中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 41 Issue 1
Jan.  2025
Turn off MathJax
Article Contents
Article Navigation >  Journal of Clinical Hepatology  > 2025  >  41(1): 84-91

The distribution pattern of traditional Chinese medicine syndromes and influencing factors for primary liver cancer: An analysis of 415 cases

DOI: 10.12449/JCH250113
  • 1.

    The First Clinical College of Shanxi University of Chinese Medicine，Taiyuan 030024，China

  • 2.

    Shanxi Institute of Traditional Chinese Medicine，Taiyuan 030012，China

Research funding:

The Fourth National Medical Master Inheritance Workshop (2022 245 1123-04);

Construction of the National TCM Inheritance and Innovation Center (202203);

General Project of Natural Science Foundation of Shanxi Province (202103021224437);

Shanxi Provincial Clinical Medical Research Center of Traditional Chinese Medicine （Cultivation） (JinKeShe ［2019］ No.61);

Shanxi Provincial Medical Science and Technology Innovation Team Project of Shanxi Provincial Health Commission (2020TD04)

More Information
  • Corresponding author: WANG Xixing， wangxx315@163.com （ORCID： 0000-0003-2444-7248）
  • Received Date: 2024-06-05
  • Accepted Date: 2024-07-29
  • Published Date: 2025-01-25
    Abstract
  •   Objective  To investigate the influencing factors for traditional Chinese medicine （TCM） syndromes of primary liver cancer， and to provide a theoretical basis for the TCM syndrome differentiation and standardized treatment of liver cancer.  Methods  TCM syndrome differentiation was performed for 415 patients who were admitted to Shanxi Institute of Traditional Chinese Medicine and were diagnosed with primary liver cancer based on pathological or clinical examinations from January 2019 to December 2023. The chi-square test was used for comparison of categorical data between groups， and the unordered polytomous logistic regression model was used to investigate the influencing factors for TCM syndromes of liver cancer.  Results  The common initial symptoms of the 415 patients with primary liver cancer included pain in the liver area （31.81%）， abdominal distension （25.30%）， abdominal pain （15.18%）， and weakness （13.98%）， and the main clinical symptoms included poor appetite （70.84%）， fatigue （69.16%）， pain in the liver area （67.47%）， poor sleep （59.04%）， abdominal distension （53.01%）， and constipation （52.53%）. There were significant differences in TCM syndromes between patients with different sexes， courses of the disease， clinical stages， Child-Pugh classes， presence or absence of intrahepatic and extrahepatic metastasis， and presence or absence of transcatheter arterial chemoembolization （TACE） and radiofrequency ablation （all P<0.05）. The logistic regression analysis showed that male sex was a risk factor for damp-heat accumulation （odds ratio ［OR］=2.036， P=0.048） and the syndrome of spleen-kidney Yang deficiency （OR=5.240， P<0.001）； a course of disease of<1 year was a risk factor for damp-heat accumulation （OR=2.837， P=0.004） and syndrome of Qi stagnation and blood stasis （OR=2.317， P=0.021）， but it was a protective factor against syndrome of spleen-kidney Yang deficiency （OR=0.385， P=0.005）； Child-Pugh class A/B was a protective factor against liver-kidney Yin deficiency （OR=0.079， P<0.001）； intrahepatic metastasis was a risk factor for liver-kidney Yin deficiency （OR=5.117， P=0.003） and syndrome of spleen-kidney Yang deficiency （OR=3.303， P=0.010）； TACE was a protective factor against liver-kidney Yin deficiency （OR=0.171， P<0.001） and syndrome of spleen-kidney Yang deficiency （OR=0.138， P<0.001）； radiofrequency ablation was a risk factor for damp-heat accumulation （OR=4.408， P<0.001） and liver-kidney Yin deficiency （OR=32.036， P<0.001）.  Conclusion  Sex， course of disease， Child-Pugh class， intrahepatic metastasis， TACE， and radiofrequency ablation are the main influencing factors for TCM syndromes of liver cancer.

     

    • FullText(HTML)
  • loading
    • References(31)
  • [1]
    Branch of Hepatobiliary Diseases, China Association of Chinese Medicine. Guideline for traditional Chinese medicine diagnosis and treatment of primary liver cancer[J]. J Clin Hepatol, 2024, 40( 5): 919- 927. DOI: 10.12449/JCH240509.

    中华中医药学会肝胆病分会. 原发性肝癌中医诊疗指南[J]. 临床肝胆病杂志, 2024, 40( 5): 919- 927. DOI: 10.12449/JCH240509.
    [2]
    BENSON AB, D’ANGELICA MI, ABBOTT DE, et al. Hepatobiliary cancers, version 2.2021, NCCN clinical practice guidelines in oncology[J]. J Natl Compr Canc Netw, 2021, 19( 5): 541- 565. DOI: 10.6004/jnccn.2021.0022.
    [3]
    ZOU WL, FANG ZJ, FENG Y, et al. Transcriptomic and genomic characteristics of intrahepatic metastases of primary liver cancer[J]. BMC Cancer, 2024, 24( 1): 672. DOI: 10.1186/s12885-024-12428-x.
    [4]
    ZENG HM, CHEN WQ, ZHENG RS, et al. Changing cancer survival in China during 2003-15: A pooled analysis of 17 population-based cancer registries[J]. Lancet Glob Health, 2018, 6( 5): e555- e567. DOI: 10.1016/S2214-109X(18)30127-X.
    [5]
    Chinese Society of Liver Cancer, Chinese Anti-Cancer Association. Chinese expert consensus on multidisciplinary treatment of liver cancer[J]. J Clin Hepatol, 2021, 37( 2): 278- 285. DOI: 10.3969/j.issn.1001-5256.2021.02.008.

    中国抗癌协会肝癌专业委员会. 中国肝癌多学科综合治疗专家共识[J]. 临床肝胆病杂志, 2021, 37( 2): 278- 285. DOI: 10.3969/j.issn.1001-5256.2021.02.008.
    [6]
    MENG HN, ZHAO L, LIU L, et al. Research progress on prevention and treatment of primary liver cancer by traditional Chinese and Western medicine[J]. Acta Chin Med Pharmacol, 2021, 49( 2): 115- 119. DOI: 10.19664/j.cnki.1002-2392.210049.

    孟唤男, 赵丽, 刘柳, 等. 中西医结合防治原发性肝癌研究进展[J]. 中医药学报, 2021, 49( 2): 115- 119. DOI: 10.19664/j.cnki.1002-2392.210049.
    [7]
    HUANG JH, ZHONG MZ, CAO PG. Diagnosis& treatment of clinical oncology[M]. Changsha: Hunan Science& Technology Press, 2010: 325- 329.

    黄俊辉, 钟美佐, 曹培国. 临床肿瘤诊断与治疗学[M]. 长沙: 湖南科学技术出版社, 2010: 325- 329.
    [8]
    General Office of National Health Commission. Standard for diagnosis and treatment of primary liver cancer(2022 edition)[J]. J Clin Hepatol, 2022, 38( 2): 288- 303. DOI: 10.3969/j.issn.1001-5256.2022.02.009.

    国家卫生健康委办公厅. 原发性肝癌诊疗指南(2022年版)[J]. 临床肝胆病杂志, 2022, 38( 2): 288- 303. DOI: 10.3969/j.issn.1001-5256.2022.02.009.
    [9]
    ZHANG BL, WU MH. Internal medicine of traditional Chinese medicine[M]. Beijing: China Press of Traditional Chinese Medicine, 2017.

    张伯礼, 吴勉华. 中医内科学[M]. 北京: 中国中医药出版社, 2017.
    [10]
    HUANG LZ. Integrated traditional Chinese and Western medicine oncology[M]. Beijing: China Press of Traditional Chinese Medicine, 2020: 231- 232.

    黄立中. 中西医结合肿瘤病学[M]. 北京: 中国中医药出版社, 2020: 231- 232.
    [11]
    SONG XL, ZHOU YN, LI J, et al. A study on standardization of data collection of cases in traditional Chinese medicine clinical liver disease specialties[J]. Chin J Integr Tradit West Med Liver Dis, 2023, 33( 5): 389- 393. DOI: 10.3969/j.issn.1005-0264.2023.005.002.

    宋幸铃, 周亚娜, 李君, 等. 中医临床肝癌病例数据采集规范化研究[J]. 中西医结合肝病杂志, 2023, 33( 5): 389- 393. DOI: 10.3969/j.issn.1005-0264.2023.005.002.
    [12]
    LI JB, MA L. Terminology of common clinical symptoms of traditional Chinese medicine(revised)[M]. Beijing: China Medical Science and Technology Press, 2015.

    黎敬波, 马力. 中医临床常见症状术语规范(修订)[M]. 北京: 中国医药科技出版社, 2015.
    [13]
    YE LH, CHENG HB, ZHANG YH, et al. Discussion on the etiology of primary liver cancer in traditional Chinese medicine[J]. Lishizhen Med Mater Med Res, 2010, 21( 10): 2627- 2628. DOI: 10.3969/j.issn.1008-0805.2010.10.096.

    叶丽红, 程海波, 章永红, 等. 原发性肝癌的中医病名病因探讨[J]. 时珍国医国药, 2010, 21( 10): 2627- 2628. DOI: 10.3969/j.issn.1008-0805.2010.10.096.
    [14]
    SHEN M, SONG C, ZHAO L, et al. Jiang Yilan discussed the experience of treating primary liver cancer through“the integration of liver and spleen, and the adjustment of three focal points”[J]. Guid J Trad Chin Med Pharm, 2023, 29( 10): 193- 196. DOI: 10.13862/j.cn43-1446/r.2023.10.039.

    申梅, 宋程, 赵磊, 等. 蒋益兰通过“肝脾一体, 兼调三焦”论治原发性肝癌经验[J]. 中医药导报, 2023, 29( 10): 193- 196. DOI: 10.13862/j.cn43-1446/r.2023.10.039.
    [15]
    CHEN D, SUN JG, WANG WQ. Professor Yin Changjian’s academic thought and clinical experience in treating primary liver cancer[J]. Chin J Integr Tradit West Med Liver Dis, 2023, 33( 9): 844- 847. DOI: 10.3969/j.issn.1005-0264.2023.009.018.

    陈迪, 孙建光, 王伟芹. 尹常健教授治疗原发性肝癌学术思想与临证经验[J]. 中西医结合肝病杂志, 2023, 33( 9): 844- 847. DOI: 10.3969/j.issn.1005-0264.2023.009.018.
    [16]
    CHEN QQ, RUI FJ, NI WJ, et al. Research progress in epidemiology and risk factors of primary liver cancer[J]. Chin Gen Pract, 2024, 27( 6): 637- 642. DOI: 10.12114/j.issn.1007-9572.2023.0479.

    陈倩倩, 芮法娟, 倪文婧, 等. 原发性肝癌的流行病学及其危险因素研究进展[J]. 中国全科医学, 2024, 27( 6): 637- 642. DOI: 10.12114/j.issn.1007-9572.2023.0479.
    [17]
    ZHANG Y, LI ZY, SHEN QM, et al. A prospective cohort study of cigarette smoking, alcohol drinking and liver cancer incidence in Chinese men[J]. J Dig Dis, 2022, 23( 8-9): 527- 534. DOI: 10.1111/1751-2980.13136.
    [18]
    MANIERI E, HERRERA-MELLE L, MORA A, et al. Adiponectin accounts for gender differences in hepatocellular carcinoma incidence[J]. J Exp Med, 2019, 216( 5): 1108- 1119. DOI: 10.1084/jem.20181288.
    [19]
    KENG VW, LARGAESPADA DA, VILLANUEVA A. Why men are at higher risk for hepatocellular carcinoma?[J]. J Hepatol, 2012, 57( 2): 453- 454. DOI: 10.1016/j.jhep.2012.03.004.
    [20]
    AI W, XIA YK, WANG XP, et al. Research progress on traditional Chinese medicine treatment of primary carcinoma of liver[J]. J Liaoning Univ Tradit Chin Med, 2018, 20( 3): 133- 136. DOI: 10.13194/j.issn.1673-842x.2018.03.039.

    艾望, 夏玉坤, 王秀萍, 等. 原发性肝癌中医药治疗研究进展[J]. 辽宁中医药大学学报, 2018, 20( 3): 133- 136. DOI: 10.13194/j.issn.1673-842x.2018.03.039.
    [21]
    WU XD, JIANG LJ. ZHOU Daihan’s experience in treatment of primary liver cancer[J]. J Tradit Chin Med, 2015, 56( 8): 648- 650. DOI: 10.13288/j.11-2166/r.2015.08.005.

    邬晓东, 姜丽娟. 周岱翰治疗原发性肝癌经验[J]. 中医杂志, 2015, 56( 8): 648- 650. DOI: 10.13288/j.11-2166/r.2015.08.005.
    [22]
    ZHOU H, LIU LL, SHI M, et al. Professor Xu Jing-Shi’s experience in strengthening the body and eliminating evils in treating liver cancer[J]. Chin J Integr Tradit West Med Liver Dis, 2022, 32( 2): 106- 109. DOI: 10.3969/j.issn.1005-0264.2022.02.003.

    周灏, 刘丽丽, 施美, 等. 徐经世国医大师扶正祛邪治疗肝癌经验总结[J]. 中西医结合肝病杂志, 2022, 32( 2): 106- 109. DOI: 10.3969/j.issn.1005-0264.2022.02.003.
    [23]
    ZOU Y, LIU ZD, LIU ZK, et al. Qi Yuanfu’s experience in treating post-embolization syndrome of primary liver cancer based on body Yin and Yang[J]. Guid J Tradit Chin Med Pharm, 2023, 29( 7): 178- 180, 198. DOI: 10.13862/j.cn43-1446/r.2023.07.035.

    邹毅, 刘寨东, 刘宗凯, 等. 齐元富基于体阴用阳治疗原发性肝癌介入栓塞后综合征经验[J]. 中医药导报, 2023, 29( 7): 178- 180, 198. DOI: 10.13862/j.cn43-1446/r.2023.07.035.
    [24]
    HE SY, QIAN J, HUO JG. Clinical experience of Xu Hefen in treating primary liver cancer[J]. Lishizhen Med Mater Med Res, 2017, 28( 7): 1736- 1737. DOI: 10.3969/j.issn.1008-0805.2017.07.073.

    何世仪, 钱峻, 霍介格. 徐荷芬治疗原发性肝癌的临床经验[J]. 时珍国医国药, 2017, 28( 7): 1736- 1737. DOI: 10.3969/j.issn.1008-0805.2017.07.073.
    [25]
    XIE LH, WANG FL, LIU JJ. Research progress in interventional therapy combined with immunotherapy for primary hepatocellular carcinoma[J]. J Changchun Univ Chin Med, 2024, 40( 5): 586- 590. DOI: 10.13463/j.cnki.cczyy.2024.05.026.

    谢林虎, 王凤玲, 刘建军. 原发性肝癌介入联合免疫治疗的研究进展[J]. 长春中医药大学学报, 2024, 40( 5): 586- 590. DOI: 10.13463/j.cnki.cczyy.2024.05.026.
    [26]
    QING XS, WANG XW, LUO GS, et al. Efficacy of drug-loaded microspheres combined with TACE in the treatment of primary liver cancer[J]. Clin Misdiagn Misther, 2024, 37( 12): 26- 30. DOI: 10.3969/j.issn.1002-3429.2024.12.006.

    卿小松, 王学文, 罗国松, 等. 载药微球联合TACE治疗原发性肝癌患者的效果观察[J]. 临床误诊误治, 2024, 37( 12): 26- 30. DOI: 10.3969/j.issn.1002-3429.2024.12.006.
    [27]
    HOU BS, LIU X, WANG HF, et al. Observation of effects on immune function and life quality of primary hepatic cancer patients with liver stagnation and spleen deficiency by modified Xiaoyao formula and Dahuang Zhechong formula combined with transcatheter arterial chemoembolization[J]. Hebei J Tradit Chin Med, 2020, 42( 9): 1346- 1350, 1368. DOI: 10.3969/j.issn.1002-2619.2020.09.016.

    侯宝松, 刘霞, 王海峰, 等. 逍遥方合大黄虫方加减联合肝动脉化疗栓塞术对原发性肝癌肝郁脾虚证患者免疫功能和生活质量的影响[J]. 河北中医, 2020, 42( 9): 1346- 1350, 1368. DOI: 10.3969/j.issn.1002-2619.2020.09.016.
    [28]
    CUI JH. Effect of Shugan Jianpi Decoction on gastrointestinal reaction after chemoembolization of hepatocellular carcinoma: An observation of 30 cases[J]. Forum Tradit Chin Med, 2019, 34( 2): 36- 37. DOI: 10.13913/j.cnki.41-1110/r.2019.02.017.

    崔军辉. 疏肝健脾汤干预肝癌化疗栓塞术后胃肠反应30例疗效观察[J]. 国医论坛, 2019, 34( 2): 36- 37. DOI: 10.13913/j.cnki.41-1110/r.2019.02.017.
    [29]
    HAN M, ZHOU J, WEI HL, et al. Progress in TCM treatment of postembolization syndrome after transcatheter arterial chemoembolization for liver cancer[J]. Chin J Inf Tradit Chin Med, 2021, 28( 11): 138- 142. DOI: 10.19879/j.cnki.1005-5304.202104041.

    韩明, 周军, 魏海梁, 等. 肝癌经导管动脉化疗栓塞术后栓塞综合征中医治疗进展[J]. 中国中医药信息杂志, 2021, 28( 11): 138- 142. DOI: 10.19879/j.cnki.1005-5304.202104041.
    [30]
    XUE LJ, GUAN Y, ZHANG L, et al. Clinical observation on acupoint application of traditional Chinese medicine for constipation after interventional therapy of liver cancer[J/CD]. Electron J Pract Gynecol Endocrinol, 2020, 7( 28): 183- 184. DOI: 10.16484/j.cnki.issn2095-8803.2020.28.121.

    薛丽娟, 管云, 张玲, 等. 中医穴位贴敷用于肝癌介入术后便秘中的临床效果观察[J/CD]. 实用妇科内分泌电子杂志, 2020, 7( 28): 183- 184. DOI: 10.16484/j.cnki.issn2095-8803.2020.28.121.
    [31]
    JI J, WEI GL, YIN GW, et al. Clinical observation on auricular points plaster therapy in treating adverse reaction of primary liver cancer after TACE[J]. West J Tradit Chin Med, 2020, 33( 10): 124- 126. DOI: 10.12174/j.issn.1004-6852.2020.10.34.

    吉晶, 魏国利, 尹国文, 等. 耳穴压豆治疗原发性肝癌TACE术后不良反应临床观察[J]. 西部中医药, 2020, 33( 10): 124- 126. DOI: 10.12174/j.issn.1004-6852.2020.10.34.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Tables(5)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (101) PDF downloads(16) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[]YesterdayPV[]TodayIP[]TodayPV[]Online[]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return